Abstract
It has been recognised that there is no need for phosphorous acid during the conversion of 1-heteroarylacetic acids to the corresponding dronic acids, as phosphorus trichloride (PCl3) is the real reagent. We could prove that the first intermediate toward the formation Risedronic acid is 3-pyridylacetyl chloride that was prepared in different ways using inorganic halides in toluene or in methanesulfonic acid (MSA). The intermediate was then reacted with two equivalents of PCl3 to afford risedronic acid after hydrolysis and pH adjustment. The pyridylacetyl chloride intermediate was identified on the basis of its esterification and amidation reaction. In MSA as the solvent, mixed anhydrides may also be formed as the intermediates from which the dronic acids may be formed in reaction with PCl3. A similar situation was anticipated for the reaction sequence of Zoledronic acid.
Keywords: Heteroarylacetic acid, Phosphorus trichloride, Heteroarylacetyl chloride, Alkyl heteroarylacetate, Heteroarylacetamide, Dronic acids, phosphorous acid, methanesulfonic acid (MSA), dronates, osteoporosis, Geminal bisphosphonates, hydroxy group, Alkyl Heteroarylacetates, pyridylacetyl chloride, Risedronic Acid, alkyl esters
Letters in Drug Design & Discovery
Title:Heteroarylacetyl Chlorides and Mixed Anhydrides as Intermediates in the Synthesis of Heterocyclic Dronic Acids
Volume: 9 Issue: 4
Author(s): Gyorgy Keglevich, Alajos Grun, Rita Kovacs, Katalin Koos, Beata Szolnoki, Sandor Garadnay, Jozsef Neu, Laszlo Drahos and Istvan Greiner
Affiliation:
Keywords: Heteroarylacetic acid, Phosphorus trichloride, Heteroarylacetyl chloride, Alkyl heteroarylacetate, Heteroarylacetamide, Dronic acids, phosphorous acid, methanesulfonic acid (MSA), dronates, osteoporosis, Geminal bisphosphonates, hydroxy group, Alkyl Heteroarylacetates, pyridylacetyl chloride, Risedronic Acid, alkyl esters
Abstract: It has been recognised that there is no need for phosphorous acid during the conversion of 1-heteroarylacetic acids to the corresponding dronic acids, as phosphorus trichloride (PCl3) is the real reagent. We could prove that the first intermediate toward the formation Risedronic acid is 3-pyridylacetyl chloride that was prepared in different ways using inorganic halides in toluene or in methanesulfonic acid (MSA). The intermediate was then reacted with two equivalents of PCl3 to afford risedronic acid after hydrolysis and pH adjustment. The pyridylacetyl chloride intermediate was identified on the basis of its esterification and amidation reaction. In MSA as the solvent, mixed anhydrides may also be formed as the intermediates from which the dronic acids may be formed in reaction with PCl3. A similar situation was anticipated for the reaction sequence of Zoledronic acid.
Export Options
About this article
Cite this article as:
Gyorgy Keglevich, Alajos Grun, Rita Kovacs, Katalin Koos, Beata Szolnoki, Sandor Garadnay, Jozsef Neu, Laszlo Drahos and Istvan Greiner , Heteroarylacetyl Chlorides and Mixed Anhydrides as Intermediates in the Synthesis of Heterocyclic Dronic Acids, Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799859963
DOI https://dx.doi.org/10.2174/157018012799859963 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Smoking and Congenital Heart Disease: The Epidemiological and Biological Link
Current Pharmaceutical Design Passive Smoking, Asthma and Allergy in Children
Inflammation & Allergy - Drug Targets (Discontinued) Current Status of Carbapenem Antibiotics
Current Topics in Medicinal Chemistry Molecular Pathologies of and Enzyme Replacement Therapies for Lysosomal Diseases
CNS & Neurological Disorders - Drug Targets Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Chromosomal Translocations as Biomarkers in Leukemia Diagnosis and Pharmacogenomics
Recent Patents on Biomarkers <i>In Silico</i> Structural and Functional Analysis of <i>Bacillus</i> Uricases
Current Proteomics Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel
Current Vascular Pharmacology Fundamental Concepts of the Angiogenic Process
Current Molecular Medicine Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging Perception of the Usefulness of Drug/Gene Pairs and Barriers for Pharmacogenomics in Latin America
Current Drug Metabolism Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging 5q- syndrome
Current Pharmaceutical Design The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi
Current Topics in Medicinal Chemistry Non-Camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Current Considerations for the Effective Safety Evaluation of Drugs In Vitro
Mini-Reviews in Medicinal Chemistry Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery